9 hours ago
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome) Market View 2025 - Commercial Sponsors Have Led Clinical Trials, with ArmaGen Heading Four Trials
Explore the competitive landscape of Mucopolysaccharidosis I (Hurler syndrome) Therapeutics. In 2024, over 1,740 cases were diagnosed across 16 countries. With one FDA-approved drug, the pipeline holds 16 promising molecules. Key insights into market trends, clinical trials, and player strategies are detailed.
Dublin, June 18, 2025 (GLOBE NEWSWIRE) -- The "Mucopolysaccharidosis I (MPS I) (Hurler syndrome): Market View" report has been added to report provides a data-driven overview of the current and future competitive landscape in Mucopolysaccharidosis I (Hurler syndrome) Therapeutics.
In 2024, there were over 1,740 diagnosed prevalent cases across 16 countries included in the epidemiology forecast. Currently, only one FDA-approved innovator drug is available for MPS I treatment. The pipeline includes 16 molecules, with one in Phase III development.
Over the past decade, commercial sponsors have led clinical trials, with ArmaGen heading four trials. Partnerships have been a significant portion of transactions across North America, Europe, and the Asia-Pacific region during this period.
Reasons to Buy
Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
Develop business strategies by understanding the trends shaping and driving the Mucopolysaccharidosis I (Hurler syndrome) Therapeutics market.
Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Mucopolysaccharidosis I (Hurler syndrome) Therapeutics market in the future.
Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.
Key Topics Covered: 1 Preface1.1 Contents1.2 Report Scope1.3 List of Tables and Figures1.4 Abbreviations2 Key Findings3 Disease Landscape3.1 Disease Overview3.2 Epidemiology Overview3.3 Treatment Overview4 Marketed Drugs Assessment4.1 Leading Marketed Drugs4.2 Overview by Mechanism of Action4.3 Overview by Molecule Type4.4 Product Profiles and Sales Forecast5 Pricing and Reimbursement Assessment5.1 Annual Cost of Therapy5.2 Time to Pricing and Reimbursement6 Pipeline Drugs Assessment6.1 Mid-to-late-stage Pipeline Drugs6.2 Overview by Development Stage6.3 Overview by Mechanism of Action6.4 Overview by Molecule Type6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)6.6 Therapy Area and Indication-specific PTSR and LoA7 Clinical Trials Assessment7.1 Historical Overview7.2 Overview by Phase7.3 Overview by Status7.4 Overview by Phase for Ongoing and Planned Trials7.5 Trials with Virtual Components7.6 Overview of Trials by Geography7.7 Single-Country and Multinational Trials by Region7.8 Top 20 Sponsors with Breakdown by Phase7.9 Top 20 Sponsors with Breakdown by Status7.10 Overview by Endpoint Status7.11 Overview by Race and Ethnicity7.12 Enrollment Data7.13 Top 20 countries for Trial Sites7.14 Top 20 Sites Globally7.15 Feasibility Analysis - Geographic Overview7.16 Feasibility Analysis - Benchmark Models8 Deals Landscape8.1 Mergers, Acquisitions, and Strategic Alliances by Region8.2 Recent Mergers, Acquisitions, and Strategic Alliances9 Commercial Assessment9.1 Key Market Players10 Future Market Catalysts11 Appendix11.1 Methodology11.2 Methodology - Sales Forecast11.3 Methodology - Pricing and Reimbursement11.4 Methodology - PTSR and LoA AnalysisFor more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
